ARTICLE | Clinical News
Xeplion regulatory update
January 3, 2011 8:00 AM UTC
CHMP issued a positive opinion recommending approval of an MAA for Xeplion paliperidone palmitate from Johnson & Johnson to treat schizophrenia. The once-monthly intramuscular injection is a long-acti...